Summary
The product Caber 1 mg, submitted by MuscleCandy and identified by batch number Lot1005, underwent independent testing by Janoshik Analytical. The analysis measured the concentration of Cabergoline, which was found to be 0.86 mg per tablet, below the labeled claim of 1 mg.
The testing process began on 19 April 2024, with the sample received on 24 April 2024, and analysis completed on 26 April 2024. These results underscore the importance of independent verification for pharmaceutical products to ensure proper dosing.
Detailed Report
Product Overview
- Manufacturer: Unknown
- Product Name: Caber 1 mg
- Active Ingredient: Cabergoline
- Batch Number: Lot1005
- Expiration Date: Not provided
- Delivery Method: Oral tablet
Sample Acquisition and Testing
- Task Number: #41413
- Testing Ordered: 19 April 2024
- Sample Received: 24 April 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: MuscleCandy
- Analysis Paid For By: MuscleCandy
Testing Results
- Specification: 1 mg (as stated on the label)
- Measured Concentration: 0.86 mg
- Accuracy: 86% of the label claim
- Variance: -14%
Verification Details
- Verification URL: https://janoshik.com/tests/41413_TRZ13UFHS1LD
Evaluation of Reseller-Submitted Testing
The analysis shows that the tested batch of Caber 1 mg contains a concentration lower than the labeled dosage. While this suggests a possible issue with consistency or quality control, it is essential to approach reseller-submitted results with caution. Independent testing of multiple batches is recommended to assess product consistency comprehensively.
Conclusion
The analysis reveals that the tested batch of Caber 1 mg contains 0.86 mg of Cabergoline, indicating a 14% deviation from the labeled dosage. Third-party testing remains crucial for quality assurance and ensuring accurate dosing in pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
